江苏先声药业有限公司 SIMCERE PHARMACEUTICAL GROUP
{{company.company_channel.channel_name}}
Media Room
{{company.company_name_local}}
{{company.company_channel.channel_name}}
Company Profile
Media Room
Findings of a Phase III Clinical Study of Sanbexin® Sublingual Tablets Published in JAMA 2024-02-21 12:26
Simcere and Connect Enter into an exclusive license and collaboration agreement for the innovative autoimmune drug Rademikibart 2023-11-23 16:04
Four innovative drugs launched in three years, HKEX -Listed Simcere Pharmaceutical Group is on the Fast Track Toward Building an Innovation-Driven Global Pharmaceutical Company 2023-04-24 18:09
Simcere Zaiming Announces Clinical Collaboration to Evaluate SIM0235, a TNFR2 Monoclonal Antibody, in Combination with KEYTRUDA® (pembrolizumab) in a Phase 1 Trial in Advanced Solid Tumors and Cutaneous T-cell Lymphoma 2023-03-14 20:00
First Prescription for COSELA® (trilaciclib) Issued in China 2023-02-09 21:00
PHASE II/III CLINICAL TRIAL OF SIMCERE'S 3CL-TARGETING ANTI-SARS-COV-2 DRUG CANDIDATE COMPLETE ALL PATIENTS ENROLLMENT 2022-12-20 19:21
Simcere and Idorsia enter into a licensing agreement for daridorexant in China 2022-11-16 08:32
Simcere Receives FDA Clearance of Investigational New Drug Application (IND) for Bi-functional Fusion Protein, SIM0237 2022-10-27 21:25
Simcere and Almirall Enter into a Licensing Agreement for IL-2 mu-Fc 2022-09-29 11:32
Simcere Pharmaceutical Announces Financial Results for 2022 H1: 27% Year-Over-Year Revenue Growth, with Innovative Drugs Accounting for 65.4% of Total Revenue 2022-09-05 13:09
Tamas Oravecz Ph.D. named SVP, CSO of the U.S. of Simcere Pharmaceutical Group 2022-09-05 13:08
SIMCERE PHARMA (HK.2096) Novel Inhibitor of COVID-19 3CLpro SIM0417 Received a Second Clinical Trial Approval in China 2022-05-18 11:56
Proprietary SARS-CoV-2 3CL Inhibitor Rapidly Progressing in Clinical Trials, Market Approval of Trilaciclib Expected in China, Simcere Reveals Global Innovation Ambition on R&D Day 2022-04-19 10:28
SIMCERE PHARMA (HK.2096) to host 2022 R&D Day 2022-04-07 21:39
Primary endpoint met in Phase III clinical trial of Trilaciclib in Chinese patients with small cell lung cancer 2022-02-24 13:34
Simcere Pharma (2096.HK) Announces a Positive Profit Alert 2022-02-23 16:22
Bijoyesh Mookerjee, M.D. named Chief Medical Officer, Oncology for Simcere Pharmaceuticals 2022-02-08 10:01
Simcere and Shanghai Institute of Materia Medica Enter a Collaboration to Jointly Develop Next-Gen COVID-19 Oral Antiviral Treatments 2021-11-23 11:22
Simcere and JW Pharmaceutical Announce Collaboration and License Agreement for Anti-Gout Drug Candidate URC-102 in China 2019-09-27 18:52
1